

1 **Comparative genomics and antimicrobial resistance profiling of *Elizabethkingia* isolates**
2 **reveals nosocomial transmission and *in vitro* susceptibility to fluoroquinolones,**
3 **tetracyclines and trimethoprim-sulfamethoxazole**

4

5 Delaney Burnard^{1,3,4#}, Letitia Gore^{2#}, Andrew Henderson¹, Ama Ranasinghe¹, Haakon
6 Bergh², Kyra Cottrell¹, Derek S. Sarovich^{3,4}, Erin P. Price^{3,4}, David L. Paterson¹, Patrick N.
7 A. Harris^{1,2*}

8 ¹University of Queensland Centre for Clinical Research, Royal Brisbane and Woman's
9 Hospital, Herston, Queensland, Australia

10 ²Central Microbiology, Pathology Queensland, Herston, Queensland, Australia

11 ³Genecology Research Centre, University of the Sunshine Coast, Sippy Downs, Queensland,
12 Australia

13 ⁴Sunshine Coast Health Institute, Birtinya, Queensland, Australia

14 #Authors contributed equally

15 ***Corresponding author:** Dr Patrick N. A. Harris

16 University of Queensland Centre for Clinical Research, Building 71/918 Royal Brisbane &
17 Women's Hospital Campus, Herston, QLD, 4029

18 **Email:** p.harris@uq.edu.au; **Tel:** +61 (0) 7 3346 6081

19 Word count abstract:436, Word count text:4,493

20 **Keywords:** *Elizabethkingia*, MDR, multidrug resistance, nosocomial, MIC, minimum
21 inhibitory concentration, antimicrobial resistance, AMR, comparative genomics

22 Abstract

23 The *Elizabethkingia* genus has gained global attention in recent years as a nosocomial
24 pathogen. *Elizabethkingia* spp. are intrinsically multidrug resistant, primarily infect
25 immunocompromised individuals, and are associated with high mortality (~20-40%).
26 Although *Elizabethkingia* infections appear sporadically worldwide, gaps remain in our
27 understanding of transmission, global strain relatedness and patterns of antimicrobial
28 resistance. To address these knowledge gaps, 22 clinical isolates collected in Queensland,
29 Australia, over a 16-year period along with six hospital environmental isolates were
30 examined using MALDI-TOF MS (VITEK[®] MS) and whole-genome sequencing to compare
31 with a global strain dataset. Phylogenomic reconstruction against all publicly available
32 genomes ($n=100$) robustly identified 22 *E. anophelis*, three *E. miricola*, two *E.*
33 *meningoseptica* and one *E. bruuniana* from our isolates, most with previously undescribed
34 diversity. Global relationships show Australian *E. anophelis* isolates are genetically related to
35 those from the USA, England and Asia, suggesting shared ancestry. Genomic examination of
36 clinical and environmental strains identified evidence of nosocomial transmission in patients
37 admitted several months apart, indicating probable infection from a hospital reservoir.
38 Furthermore, broth microdilution of the 22 clinical *Elizabethkingia* spp. isolates against 39
39 antimicrobials revealed almost ubiquitous resistance to aminoglycosides, carbapenems,
40 cephalosporins and penicillins, but susceptibility to minocycline, levofloxacin and
41 trimethoprim/sulfamethoxazole. Our study demonstrates important new insights into the
42 genetic diversity, environmental persistence and transmission of Australian *Elizabethkingia*
43 species. Furthermore, we show that Australian isolates are highly likely to be susceptible to
44 minocycline, levofloxacin and trimethoprim/sulfamethoxazole, suggesting that these
45 antimicrobials may provide effective therapy for *Elizabethkingia* infections.

46 **Importance**

47 *Elizabethkingia* are a genus of environmental Gram-negative, multidrug resistant,
48 opportunistic pathogens. Although an uncommon cause of nosocomial and community-
49 acquired infections, *Elizabethkingia* spp. are known to infect those with underlying co-
50 morbidities and/or immunosuppression, with high mortality rates of ~20-40%.
51 *Elizabethkingia* have a presence in Australian hospitals and patients; however, their origin,
52 epidemiology, and antibiotic resistance profile of these strains is poorly understood. Here, we
53 performed phylogenomic analyses of clinical and hospital environmental Australian
54 *Elizabethkingia* spp., to understand transmission and global relationships. Next, we
55 performed extensive minimum inhibitory concentration testing to determine antimicrobial
56 susceptibility profiles. Our findings identified a highly diverse *Elizabethkingia* population in
57 Australia, with many being genetically related to international strains. A potential
58 transmission source was identified within the hospital environment where two transplant
59 patients were infected and three *E. anophelis* strains formed a clonal cluster within the
60 phylogeny. Furthermore, near ubiquitous susceptibility to tetracyclines, fluoroquinolones and
61 trimethoprim/sulfamethoxazole was observed in clinical isolates. We provide new insights
62 into the origins, transmission and epidemiology of *Elizabethkingia* spp., in addition to
63 understanding their intrinsic resistance profiles and potential effective treatment options,
64 which has implications to managing infections and detecting outbreaks globally.

65

66 Introduction

67 The genus *Elizabethkingia* (formerly *Chryseobacterium*), comprise a group of environmental
68 bacteria that have traditionally been isolated from soil and water environments¹⁻⁴. As
69 opportunistic pathogens, *Elizabethkingia* spp. can cause sporadic nosocomial outbreaks and
70 infections in immunocompromised or at-risk individuals^{1,2,5-8}. Infections have been
71 documented worldwide such as those in the Central African Republic⁹, Mauritius¹⁰,
72 Singapore¹¹, Taiwan¹² and the USA⁶, suggesting a comprehensive global distribution that is
73 yet to be fully described. Often, the source of *Elizabethkingia* spp. infection remains unclear
74 and routes of transmission are still to be defined^{2,6,9,12-16}. However, previous investigations
75 have suggested that shared water reservoirs within hospitals may be an overlooked source of
76 infection^{1,2,17}.

77

78 As an understudied pathogen, taxonomic assignment within the *Elizabethkingia* genus is
79 ongoing. Recently, a formal taxonomic revision using whole-genome sequencing (WGS) left
80 the previously described species *E. meningoseptica* and *E. miricola* unchanged, while the
81 proposed species *E. endophytica*¹⁸ is now considered a clone within *E. anophelis*¹⁹⁻²¹. Several
82 new species, *E. bruuniana*, *E. ursingii*, and *E. occulta* have recently been described³⁻⁵. It is
83 also now recognised that *E. anophelis*, not *E. meningoseptica*, is the primary species causing
84 human infection, although clinical presentations may be very similar^{4,13,22-24}. The remaining
85 members of the genus are thought to be much less prevalent in human disease; however,
86 difficulties in accurately identifying *E. miricola*, *E. bruuniana*, *E. ursingii*, and *E. occulta*
87 from clinical specimens has hindered appropriate recognition and characterisation of these
88 species⁴.

89

90 Common clinical presentations of *E. anophelis* infections include primary bacteraemia,
91 pneumonia, sepsis and meningitis in neonates^{7,14,22,23}. Risk factors associated with *E.*
92 *anophelis* infection consist of being male, having underlying chronic medical conditions such
93 as malignancy or diabetes mellitus, and admission to critical care or neonatal units^{13,22,23,25}.
94 Currently, approximately 80% of *E. anophelis* infections are considered hospital-acquired
95 with mortality rates ranging from 23-26%^{22,23,25}. Similarly, *E. meningoseptica* infections also
96 present as neonatal meningitis and/or sepsis but can also cause infections in most organ
97 systems. Primary bacteraemia is the most common presentation, occurring more often in
98 hospitalised patients and those with underlying co-morbidities^{8,12}. The mortality rate of *E.*
99 *meningoseptica* infection is between 23-41%, with higher rates in individuals where
100 premature birth, shock or admission to a critical care unit has taken place^{12,26}. To date, the
101 largest outbreak was caused by community-acquired *E. anophelis* in Wisconsin, USA, from
102 2015-2016. A total of 66 individuals were infected and the outbreak spread to the
103 neighbouring states of Illinois and Michigan⁶. Comparative genomics characterised unique
104 mutations in an integrative conjugative element (ICE) insertion in the *MutY* gene in all
105 infecting strains as well as a mutation in the *MutS* gene in hypermutator strains, which may
106 have accelerated the transmission of the outbreak clone⁶.

107

108 Poorly understood intrinsic multidrug resistance (MDR) in *E. anophelis* and *E.*
109 *meningoseptica* infections has led to inappropriate empiric antibiotic therapy, especially in
110 patients with underlying co-morbidities, in critical care^{12,26} or neonatal units^{1,2,8,13,15,16,27},
111 resulting in high mortality rates. There are currently no established minimum inhibitory
112 concentration (MIC) breakpoints for *Elizabethkingia* spp., causing reported susceptibility
113 rates to vary among studies. Despite interpretation differences, *Elizabethkingia* are generally
114 considered resistant to carbapenems, cephalosporins, aminoglycosides, and most β -lactams

115 even in combination with β -lactamase inhibitors (except for piperacillin/tazobactam).
116 Minocycline, levofloxacin, trimethoprim/sulfamethoxazole and piperacillin/tazobactam are
117 the most common antimicrobials that have been tested and generally demonstrate widespread
118 susceptibility^{4,6,23–25,28}. Interestingly, *in vitro* susceptibility to the Gram-positive glycopeptide
119 vancomycin has been documented in *Elizabethkingia* spp., resulting in vancomycin being
120 suggested as a therapy^{4,29–31}. Based on these results the empiric antibacterial therapy of
121 choice for *Elizabethkingia* spp. infections is not clear, but should ideally be guided by further
122 MIC profiling^{7,23,25,31}.

123

124 Here, we present one of the largest comparative genomic analyses of the *Elizabethkingia*
125 genus to date, which includes 22 newly described clinical isolates and six hospital
126 environmental isolates from Australia, a previously underrepresented geographic area. The
127 speciation accuracy of the VITEK[®] MS v3.2 database was assessed, in addition to a
128 comprehensive examination of clinical isolates using both genomic data and MIC testing
129 across 39 antimicrobials. Our results provide valuable insights into global *Elizabethkingia*
130 relationships, speciation accuracy, transmission, the extent of intrinsic antimicrobial
131 resistance and options for potential effective antimicrobial therapy to combat these
132 opportunistic pathogens.

133

134

135 **Methods**

136 *Ethics statement*

137 This project was reviewed by the chairperson of a National Health and Medical Research
138 Council (NHMRC) and registered with The Royal Brisbane and Women's Hospital Human
139 Research Ethics Committee (HREC) (EC00172) and was deemed compliant with the
140 NHMRC guidance "Ethical considerations in Quality Assurance and Evaluation Activities"
141 2014 and exempt from HREC review.

142 *Isolates and initial identification*

143 Twenty-two clinical *Elizabethkingia* spp. isolates collected in Queensland, Australia over a
144 16-year period (2002-2018) were included in this study (Table 1). Isolates were collected by
145 two methods. First, laboratory database storage records from multiple public and private
146 laboratories in Queensland were searched for *Elizabethkingia* spp. or *Chryseobacterium*
147 *meningoseptica*. Second, isolates identified by current laboratory identification systems as
148 *Elizabethkingia* spp. were collected prospectively from both private and public pathology
149 laboratories throughout the state of Queensland between January 2017 and October 2018. All
150 isolates were stored at -80°C with low temperature bead storage systems. Single colonies
151 were double passaged from clinical specimens on 5% horse blood agar (Edwards Group
152 MicroMedia, Narellan, NSW, Australia) then subjected to identification via VITEK® MS
153 Knowledge Base v3.2 (bioMérieux, Murarrie, QLD, Australia) which is inclusive of *E.*
154 *anophelis*, *E. miricola* and *E. meningoseptica*.

155 Furthermore, six environmental isolates were collected in 2019 from a participating hospital
156 via swabbing various surfaces throughout the environment (Table 1). Specimens were plated
157 onto 5% horse blood agar and *Elizabethkingia* spp. colonies were double passaged to ensure
158 purity then subjected to identification via VITEK® MS Knowledge Base v3.2.

159

160 *DNA extraction, whole-genome sequencing and genome assembly*

161 DNA was extracted using the DNeasy Ultra Clean Microbial extraction kit (Qiagen,
162 Chadstone, VIC, Australia) according to the manufacturer's instructions. Purified DNA was
163 quantified using both the NanoDrop 3300 spectrophotometer and the Qubit™ 4 fluorometer
164 (Thermo Fisher Scientific). Sequencing libraries were generated using the Nextera Flex DNA
165 library preparation kit and sequenced on the MiniSeq™ System (Illumina Inc.®, San Diego,
166 CA, USA) on a high output 300 cycle cartridge according to the manufacturer's instructions.
167 Comparative genomic analyses were performed across a large *Elizabethkingia* data set
168 ($n=128$; Table S1), including the 28 Australian genomes generated in the current study (Table
169 1), to assign species and to assess intraspecific and geographical relationships among strains.
170 Publicly available *Elizabethkingia* Illumina reads ($n=119$) were downloaded from the NCBI
171 Sequence Read Archive database (January 2019), and *Elizabethkingia* spp. assemblies were
172 downloaded from the GenBank database ($n=109$). Publicly available Illumina reads were
173 quality-filtered with Trimmomatic v0.38³² and subject to quality control assessments with
174 FastQC³³, followed by downsizing using Seqtk to 40x coverage³⁴. For assemblies without
175 accompanying Illumina data, synthetic paired-end reads were generated with ART
176 MountRainier-2016.06.05³⁵. Genomes were limited to one representative per strain, and only
177 high-quality sequence reads according to FastQC were included to avoid errors in
178 phylogenomic reconstruction ($n=100$; Table S1). The genomes were assembled using SPAdes
179 v3.13.0³⁶ and annotated with Prokka v1.13³⁷ (Table S2).

180

181 *Phylogenomic reconstruction*

182 The comparative genomics pipeline SPANDx v3.2³⁸ was used under default settings to
183 identify orthologous, biallelic, core-genome single-nucleotide polymorphism (SNP) and short
184 insertion-deletion (indel) characters among the 128 *Elizabethkingia* genomes. *E. anophelis*
185 NUHP1, *E. miricola* CSID3000517120, *E. meningoseptica* G4120 and *E. bruuniana* G0146
186 (GenBank accession numbers NZ_CP007547.1, NZ_MAGX00000000.1, NZ_CP016378.1
187 and NZ_CP014337.1 respectively) were used as reference genomes for SPANDx read
188 mapping alignment. Outputs from SPANDx were used to generate maximum parsimony trees
189 using PAUP version 4.0a³⁹ and visualised in FigTree v4.0
190 (<http://tree.bio.ed.ac.uk/software/figtree>). From the 128 genomes 127,236 SNPs and were
191 used to construct the *Elizabethkingia* genus phylogeny (Figure 1.). Within-species
192 phylogenies were also constructed using 121,827 SNPs from 71 genomes for *E. anophelis*
193 (Figure 2), 135,087 SNPs from 18 genomes for *E. miricola* (Figure 3), 61,500 SNPs from 22
194 genomes for *E. meningoseptica* (Figure 4) and 82,680 SNPs from 10 genomes for *E.*
195 *bruuniana* (Figure 5) phylogenies respectively. All phylogenies were statistically tested with
196 1000 bootstrap replicates. Branch support of less than 0.8 is shown in figures. To assess SNP
197 and indel differences amongst closely related strains, the earliest collected strain was used as
198 the reference in SPANDx, SNP and indel variants that had passed quality filtering were
199 visualised in Tablet 1.19.09.03⁴⁰ and Geneious Prime 2019 2.1⁴¹ (Table 2).

200

201 *Minimum Inhibitory Concentration (MIC) testing*

202 *Elizabethkingia* spp. clinical isolates were subjected to broth microdilution to determine
203 MICs for 39 clinically relevant antimicrobials consistent with or complementary to previous
204 *Elizabethkingia* studies^{12,23,28,42} (Tables 3 & 4). Custom Gram-negative Sensititre MIC Plates
205 (ThermoFisher Scientific, Scoresby, VIC, Australia) were used according to manufacturer's

206 instructions. *E. bruuniana* isolate, EkQ11, was excluded from MIC analyses due to poor
207 growth. *Elizabethkingia* spp. isolates were compared against the European Committee on
208 Antimicrobial Susceptibility Testing (EUCAST) pharmacokinetic-pharmacodynamic (PK-
209 PD) “non-species” breakpoints⁴³ and the non-*Enterobacteriaceae* breakpoints as per the
210 Clinical and Laboratory Standards Institute (CLSI) M45 guidelines^{44–46}.

211

212 *In silico antimicrobial resistance (AMR) gene predictions*

213 Clinical *Elizabethkingia* spp. WGS data were subject to ABRicate set to the CARD database
214 to predict AMR genes (<https://github.com/tseemann/abricate>) and RAST for a secondary
215 confirmation^{42,47,48}. Geneious prime 2019.2.1 and BLAST
216 (<https://blast.ncbi.nlm.nih.gov/Blast.cgi>) were used to generate single protein sequence
217 alignments⁴¹.

218

219 *Data availability*

220 Illumina sequence data for the 28 *Elizabethkingia* spp. genomes described in this study have
221 been deposited in the NCBI SRA database under identifier SRP225137, BioProject
222 PRJNA576977 (BioSample accessions: SAMN13016226-SAMN13016247 and
223 SAMN14081590- SAMN14081595).

224 **Results**

225 *Elizabethkingia* speciation using comparative genomics vs mass spectrometry

226 Phylogenomic reconstruction of 100 *Elizabethkingia* reference genomes collected globally
227 over the past 50 years and the 28 Australian clinical and environmental *Elizabethkingia* spp.
228 genomes robustly identified as *E. anophelis* ($n=22$), *E. miricola* ($n=3$), *E. meningoseptica*
229 ($n=2$) and *E. bruuniana* ($n=1$) (Figure 1; Table S1). Eleven speciation errors were identified
230 in the publicly available dataset consisting of two speciation errors within the *E. anophelis*
231 clade, five within the *E. bruuniana* clade and one within the *E. miricola* clade (Figure 1).
232 Additionally, comparison of the VITEK[®] MS Knowledge Base v3.2 with genomic species
233 assignments of the Australian isolates resulted in one speciation error in this study,
234 incorrectly identifying *E. bruuniana* as *E. miricola* (Table 1).

235

236 *Australian Elizabethkingia* and global relatedness

237 Australian *Elizabethkingia* spp. displayed no distinct phylogeographical signal within the
238 genus phylogeny as they disseminated across the phylogenetic tree (Figure 1.) However,
239 multiple introduction events appear to have taken place, as at least five clades with Australian
240 representatives are branching with international strains, for example: EkQ1, 10 & 13
241 branching with HvH-WGS333 and EM_CHUV from Denmark and Switzerland respectively,
242 EkS4 branching with CSID_3015183679 from Wisconsin, environmental strains EK1,3,4,5
243 branching with NUH11 and 6 from Singapore, EkQ15 branching with F3201 from Kuwait
244 and EkQ4 clustering with 61421PRCM, G4120 and UBA907 from China, France and New
245 York, respectively (Figure 1). No Australian *Elizabethkingia* isolate was identical to a
246 previously described isolate, with those appearing to be near identical in the phylogenies
247 separated by 16-284 SNPs (Figures 1-5). Australian *E. anophelis* are not closely related to

248 Wisconsin, USA outbreak strains (Figure 1, Figure 2). Clinical isolates EkQ17, Q5, S2 and
249 environmental isolates EK2 and EK6 branched off the Wisconsin, USA outbreak cluster,
250 diverging as a distantly related unique lineage separated by an estimated 20,400 SNPs and
251 500 indels using CSID_3015183681 as the reference strain. The truncation of the C-terminal
252 of MutY and MutS, characteristic of the outbreak and hypermutator strains were not evident
253 in Australian strains in the amino acid alignment. The 2019 hospital environmental isolates
254 EK1, EK3, EK4, and EK5, collected from various wards handwashing sinks or toilet
255 environments from the same hospital as EkQ5-EkQ17-EK6-EK2, are closely related to two
256 2012 Singaporean isolates, NUH6 and NUH11. These isolates are separated by 656-867
257 SNPs and 41-72 indels, and all share a clade with 2016 outbreak isolate CSID_3015183686,
258 which differs from the Singapore isolates by an estimated 9800 SNPs and 260 indels.

259

260 *Evidence of E. anophelis nosocomial transmission*

261 Two instances of recent closely related Australian *E. anophelis* isolates were identified on
262 two separate lineages by phylogenetic analysis (Figure 2), both with bootstrap support of 1.
263 In the first instance EkM1 and EkM2 were collected from the same patient one month apart,
264 branching as unique lineage with clinical isolate EkQ6 from a patient in a different hospital.
265 All strains were collected in 2018 and did not show evidence of within host evolution (Figure
266 2).

267 In the second instance, diverging from the Wisconsin outbreak cluster in the *E. anophelis*
268 phylogeny are five epidemiologically linked clinical isolates EkQ5, EkQ17, Eks2 and
269 environmental isolates EK2 and EK6 (Figure 2). SNP and indel comparisons between clinical
270 strains EkQ5 and EkQ17 revealed a difference of eight SNPs and one indel between two
271 different patients admitted into the same transplant ward nine months apart in 2018.

272 Epidemiologically, these three isolates appear to be linked to a single environmental source
273 within the transplant ward.

274 Mutational differences between EkQ5-EkQ17 and EK6 were mostly non-synonymous in
275 nature, consistent with adaptive evolution. Of the two SNPs separating EkQ17 and EK6, one
276 resulted in a missense (E168K) mutation in a hypothetical protein (Ek00046). Between EkQ5
277 and EK6, four SNPs resulted in missense mutations, and two caused nonsense mutations in
278 the penicillin-binding protein E (PbpE) and a sugar transporter protein that increased protein
279 length, likely leading to altered or lost protein function (Table 2). In addition, the indel
280 mutation accrued by EkQ5 resulted in a frameshift mutation that elongated hypothetical
281 protein (Ek02802) by nine residues, potentially altering its function.

282 Another hospital environmental isolate, EK2, was linked to the EkQ5-EkQ17-EK6 clade
283 according to phylogenetic analysis, differing by 38 SNPs and 16 indels (Figure 2). This
284 isolate was collected in 2019 from a sink drain in the infectious disease ward adjacent to the
285 transplant ward where EkQ5, EkQ17 and EK6 were isolated. A more distantly related clinical
286 isolate, EkS2, also clustered within the same clade as the EkQ5-EkQ17-EK6-EK2 isolates but
287 differed from these isolates by 3552 SNPs and 120 indels. Consistent with the phylogenomic
288 findings, EkS2 was not epidemiologically linked to the EkQ5-EkQ17-EK6-EK2 isolates,
289 being isolated from a patient admitted to a different hospital in 2015.

290

291 *Minimum Inhibitory Concentrations (MIC)*

292 A total of 39 clinically relevant antimicrobials were tested across the 22 clinical *E. anophelis*,
293 *miricola* and *meningoseptica* isolates. Modal MICs were relatively consistent within and
294 between species and predominantly sat on the higher end of the ranges tested (Tables 3 & 4).
295 *Elizabethkingia* does not have a defined clinical breakpoint, therefore species were examined

296 against the EUCAST “non-species” and CLSI “non-Enterobacteriaceae” PK-PD breakpoints.
297 EUCAST breakpoints suggest Australian strains have the greatest resistance to
298 cephalosporins, carbapenems and penicillins even in combination with β -lactamase inhibitors
299 (amoxicillin-clavulanic acid, piperacillin-tazobactam and ampicillin-sulbactam).
300 Furthermore, the CLSI breakpoints suggest high levels of resistance to amikacin, gentamicin,
301 tobramycin and chloramphenicol. From the MIC values (Tables 3 & 4), only a select few
302 antimicrobials had modal MICs in the lower range, including tetracyclines (doxycycline 2
303 $\mu\text{g}/\text{mL}$ and minocycline 0.5-1 $\mu\text{g}/\text{mL}$), fluoroquinolones (ciprofloxacin 0.25 $\mu\text{g}/\text{mL}$ and
304 levofloxacin 0.25 $\mu\text{g}/\text{mL}$) and trimethoprim-sulfamethoxazole 1 $\mu\text{g}/\text{mL}$ (Tables 3 & 4). Only
305 minocycline achieved 100% susceptibility across all *E. anophelis* strains using the CLSI non-
306 Enterobacteriaceae PK-PD breakpoints. Rifampicin and azithromycin do not have
307 corresponding EUCAST or CLSI PK-PD breakpoints; however, their respective modal MICs
308 are also on the lower end of the ranges tested, suggesting the potential for susceptibility. One
309 *E. anophelis* isolate EkQ6 was responsible for the low MICs observed across the
310 antimicrobials tested, remaining susceptible to cephalosporins and carbapenems, in addition
311 to the fluoroquinolones, tetracyclines and trimethoprim-sulfamethoxazole.

312

313 *In silico* antimicrobial resistance (AMR) genes

314 All 22 clinical *Elizabethkingia* spp. genomes carried all three previously described β -
315 lactamases characteristic of *Elizabethkingia*. The chromosomal extended spectrum β -
316 lactamase *bla*_{CME} encodes cephalosporin and β -lactamase activity, while metallo- β -lactamases
317 *bla*_{BlaB}, and *bla*_{GOB} encode activity against carbapenems and β -lactam/ β -lactamase inhibitor
318 combinations. The metallo- β -lactamase *bla*_{BlaB}, carried a missense mutation of *bla*_{BlaB} ^{Δ T16A} in
319 EkQ6. Except for *E. bruuniana* EkQ11, all Australian *Elizabethkingia* spp. genomes carried

320 the vancomycin resistance protein VanW. Three *E. miricola* and the *E. bruuniana* isolate
321 carried an AmpC variant with 94-95% sequence similarity to AmpC identified in *E.*
322 *anophelis* and *E. miricola* genomes (accession numbers CP006576, CP007547 and
323 CP011059). All isolates carried a conserved AmpG, with three strains exhibiting AmpG^{ΔM1-}
324 ^{A243} and one strain exhibiting AmpG^{ΔM1-A3} 5' truncations.

325 **Discussion**

326 *Elizabethkingia* spp. have caused serious nosocomial infections and outbreaks globally yet
327 have received little attention to date. This study aimed to fill knowledge gaps surrounding
328 diversity, origin and transmission events of clinical and environmental *Elizabethkingia* spp.
329 isolates from Australia, a previously unstudied geographic, using comparative genomics. In
330 parallel, we also describe the antimicrobial resistance profiles among Australian clinical
331 *Elizabethkingia* spp. isolates from broth microdilution data against 39 antimicrobials, to
332 further increase our understanding of suitable treatment options.

333

334 *Elizabethkingia* speciation using comparative genomics vs mass spectrometry

335 The 28 Australian *Elizabethkingia* isolates were identified as *E. anophelis*, *E.*
336 *meningoseptica*, *E. miricola* and *E. bruuniana*, with *E. anophelis* as the primary infecting
337 species in Australia, similar to recent global reports^{7,22,25}. These isolates, from a previously
338 under-represented geographic area, contribute to ~20% of the diversity seen in the current
339 reference genome database. Despite previous review of identification failing using mass
340 spectroscopy for species other than *E. anophelis* and *E. meningoseptica*⁴, the VITEK[®] MS
341 Knowledge Base v3.2 performed reliably in this study with 96.2% accuracy. *E. bruuniana*
342 was the only *Elizabethkingia* species that could not be accurately identified, instead identified
343 as the sister species *E. miricola*. This could be due to the species not yet being present in the
344 database, or perhaps *E. miricola* and *E. bruuniana* being variations of the same species, as
345 many previous speciation errors were seen in the genus phylogeny (Figure 1). Nevertheless,
346 identification of *E. miricola* should be taken with caution until the database has been
347 upgraded with the capabilities to differentiate between the sister-species.

348

349 *Australian Elizabethkingia and global relatedness*

350 Our Australian clinical isolates were unique, yet still closely related in comparison to the
351 geographically dispersed reference *Elizabethkingia* spp. genomes (Figures 2-5). The
352 Australian isolates were well dispersed throughout their respective species-specific
353 phylogenies branching with geographically diverse isolates from both clinical and
354 environmental settings. Recently, DNA–DNA hybridization and average nucleotide identity
355 have allowed for the re-classification of *E. miricola* strains ATCC 33958, BM10, and
356 EM798-26 to *E. bruuniana*^{3,25,49}. Further to these corrections, using comparative genomics
357 we suggest the re-classification of *E. miricola* strains 6012926 and CIP111047 to *E.*
358 *bruuniana*, *E. meningoseptica* strains NCTC10588 and NCTC10586 to *E. anophelis* and
359 lastly, *E. meningoseptica* NCTC11305 to *E. miricola* (Figure 1). Evidence from past studies
360 have described the structure of *E. anophelis* phylogenies to comprise of two and six
361 lineages^{6,50}, in this study we identified six lineages, yet as sampling continues this may
362 expand (Figure 2).

363

364 Several *E. anophelis* isolates from this study cluster with the Wisconsin outbreak strains from
365 2016, the most pathogenic *Elizabethkingia* outbreak to date⁶. Outbreak and hypermutator
366 stains have been characterised by their ICE insertion and truncations at the C terminal in both
367 the MutS and MutY protein sequences respectively⁶. The MutS and MutY protein sequences
368 in our clinical isolates aligned with few non-synonymous amino acid changes and no
369 truncations, therefore it is unlikely the Australian clinical isolates would display the outbreak
370 or hypermutator phenotype, which could be responsible for the increased pathogenesis of the
371 Wisconsin strains. Pathogenicity islands were identified in both Australian and Wisconsin *E.*

372 *anophelis* strains, suggesting they may play an important role in the species survival or
373 pathogenesis.

374

375 Hospital environmental isolates EK1, 3, 4, 5 formed a clonal cluster and were closely related
376 to two 2012 Singaporean clinical isolates, NUH6 and NUH11. The Australian environmental
377 isolates differed from the Singaporean isolates by 656-867 SNPs and 41-72 indels suggesting
378 shared ancestry.

379

380 *Potential nosocomial transmission of E. anophelis in a transplant ward*

381 A recent case of hospital acquired *E. anophelis* infection was suggested by the identification
382 of a clonal cluster comprised of clinical and environmental isolates in this study. A pair of
383 Australian *E. anophelis* clinical isolates EkQ5 and EkQ17, collected almost a year apart in
384 2018 from two patients on the transplant ward were characterised as differing by only eight
385 SNPs and one deletion. Additionally, it was found that the hospital environmental sample
386 collected from a hand washing sink in the same transplant ward in late 2019 only differed to
387 clinical sample EkQ5 by six of the above SNPs and the one deletion. The combination of
388 clinical and environmental genomic data, with such low genetic diversity suggests these
389 strains were transmitted via the common reservoir of the hand-washing sink given the
390 extended time frame between patient infection and environmental collection. Near identical
391 isolates have been described previously within *E. anophelis*, such as environmentally
392 collected OSUVM-1 and 2 isolates⁵¹, hospital outbreak strains NUHP⁵² and Wisconsin CSID⁶
393 strains, suggesting low genetic variation is not unusual amongst *E. anophelis* infections. The
394 relatedness of sink or toilet environment hospital isolates EK4 and EK5 from the transplant
395 ward, to EK1 and EK3 in the oncology ward suggest that another transmission event may

396 have also taken place, despite not identifying a related clinical isolate. Previous studies have
397 reported contaminated communal water sources as a reservoir for *Elizabethkingia* spp.
398 infections within hospitals^{1,17}, with hand-washing stations in a paediatric intensive care unit
399 the source of several *Elizabethkingia* spp. infections in Singapore, where staff transmitted the
400 infection after handwashing². Although, direct human-to-human transmission is seen in many
401 other nosocomial infections^{53,54} and vertical transmission has been reported in *E. anophelis*⁵⁵
402 the role human-to-human transmission has in *Elizabethkingia* infections still remains unclear.
403 However, given the severity of infection, known patient risk factors and the suggested
404 longevity of the bacteria in the environment, the potential for horizontal transmission should
405 not be overlooked.

406

407 *Minimum Inhibitory Concentrations (MIC) testing*

408 The MIC data generated in this study confirm the Australian clinical *Elizabethkingia* spp.
409 isolates (with the exception of isolate EkQ6), like those in previous studies, are resistant to
410 many antimicrobial classes, including cephalosporins, carbapenems and aminoglycosides
411 (Tables 3 & 4)^{12,23,24,28,56,56}. From the literature, there is very little variation in *E. anophelis*
412 antimicrobial resistance profiles among isolates from America, Southeast Asia and South
413 Korea. For example, approximately 75-100% of *E. anophelis* isolates were reported as
414 resistant to trimethoprim-sulfamethoxazole^{6,23-25,28}, while 75% of Australian strains remained
415 susceptible. Additionally, 88-95% of isolates were susceptible to piperacillin-
416 tazobactam^{6,23,25,28}, while 68-70% of Australian and South Korean²⁴ isolates were resistant.
417 Vancomycin has been suggested as potential therapy for *E. meningoseptica* infections,
418 therefore we screened our *E. anophelis* strains against vancomycin and additional
419 antimicrobials with Gram-positive activity, such as teicoplanin. Despite some advocating for

420 vancomycin use in *Elizabethkingia* infections^{4,29-31}, our data shows resistance within
421 Australian clinical isolates, as MIC values were on the high end of the range tested and all
422 isolates, with the exception of *E. bruuniana* (EkQ11), carry the *vanW* gene. This is the first
423 set of MIC data for teicoplanin and, with a modal MIC of 32 µg/mL, these strains appear to
424 be resistant. Similar to that of the Wisconsin outbreak strains⁶, Australian *Elizabethkingia*
425 spp. strains may be susceptible to azithromycin, as the modal MIC of 4 µg/mL is on the lower
426 end of the range tested. Although doxycycline is not often tested on *E. anophelis* in the
427 literature, unlike in our study, others have found their strains highly susceptible²⁸. EUCAST
428 breakpoints suggest 6.25% and 43.75% of Australian *E. anophelis* isolates are resistant to
429 levofloxacin and ciprofloxacin respectively. Variability in fluoroquinolone susceptibility has
430 also been observed in the majority of southeast Asian and American strains^{6,23,25,28,31}.
431 Numerous antimicrobials have been tested across *E. anophelis* isolates in previous studies,
432 although susceptibility to multiple antimicrobial classes like that observed in EkQ6, has not
433 been reported previously. Further testing of *E. anophelis* isolates from Australia and abroad
434 would determine if this type of sensitivity is unique to a subset of Australian strains or is
435 present globally.

436

437 *In Silico Antimicrobial Resistance (AMR) genes*

438 Antimicrobial resistance genes *bla_{BlaB}*, *bla_{GOB}* and *bla_{CME}* were identified within the genomes
439 of all clinical *Elizabethkingia* spp., linking directly to their observed MIC profiles. All
440 isolates with the exception of EkQ6 were resistant to cephalosporins and penicillins (*bla_{CME}*),
441 carbapenems and β-lactam/β-lactamase inhibitor combinations (*bla_{BlaB}*, and *bla_{GOB}*)^{4,57-59}.
442 However, fluoroquinolone resistance varied in our collection, as described above. Previous
443 studies have described resistance being mediated by a single step amino acid substitution

444 (Ser83Ile or Ser83Arg) in *gyrA*^{23,25,60}, which was not identified in any of the clinical
445 *Elizabethkingia* sp. isolates. The absence of the mutation has also been reported recently for a
446 single isolate in Taiwan²⁸. Previous studies have linked DNA topoisomerase IV to an
447 assistance type role in fluoroquinolone resistance for *Elizabethkingia* spp.^{28,60}, although this
448 was not identified in our clinical isolate collection either.

449 In addition, clinical *E. anophelis* isolate EkQ6 carried several mutations not commonly
450 described in proteins BlaB and TopA^{25,28,30,61}, yet remained susceptible to cephalosporins,
451 carbapenems, tetracyclines and fluoroquinolones. The substitutions and deletions
452 respectively, may or may not be linked to the susceptibility of this isolate. The observed
453 susceptibility in EkQ6 could have occurred from in-host adaption, evolution in an
454 environment where exposure to antimicrobials is minimal or mutations that have
455 inadvertently resulted in an adaption to a susceptible phenotype. Comparative genomics
456 including more susceptible isolates such as EkQ6 would provide great insight into the
457 intrinsic antimicrobial resistance mechanisms of *Elizabethkingia* species^{30,62,63}.

458

459 *Potential antimicrobial therapy for Elizabethkingia spp.*

460 As *Elizabethkingia* spp. are predominantly isolated from the bloodstream and possess
461 chromosomally encoded MBL-type carbapenemases, therapy is guided by multiple factors
462 such as patient condition prior to infection, the severity and source of infection, previous
463 exposure to antimicrobials and individualised MIC data. In this study, Australian isolates
464 appear to be susceptible to fluoroquinolones, tetracyclines and trimethoprim-
465 sulfamethoxazole. Only levofloxacin and minocycline demonstrated 100% susceptibility
466 using CLSI PK-PD breakpoints. Fluoroquinolone treatment alone has proven to be successful
467 in *Elizabethkingia* spp. infections⁶⁴, yet some recommend combination therapy⁶⁵ in order to

468 mitigate high-level fluoroquinolone resistance for those susceptible to single step mutations.
469 From our and other studies, susceptibility is clearly strain dependent. Our findings suggests
470 rifampicin⁶⁶ or azithromycin could also be effective antimicrobials, although this would
471 require further testing. With this in mind and the recent success of newer antimicrobials
472 against MDR Gram-negative bacteria⁶⁷⁻⁶⁹, it would be of value to further test *Elizabethkingia*
473 spp. against newer antimicrobials such as cefiderocol⁷⁰. Although sporadic, *Elizabethkingia*
474 spp. infections have the potential for high mortality rates and nosocomial outbreaks with few
475 treatment options, therefore additional antimicrobial therapies are required and should be
476 investigated further.

477 **Conclusions**

478 This study has characterised the diversity of Australian *Elizabethkingia* spp. using
479 comparative genomics and antimicrobial resistance genotypically and phenotypically. We
480 have revealed significant strain diversity within Australia and have shown that the VITEK[®]
481 MS Knowledge Base v3.2 can accurately identify *E. anophelis*, *E. meningoseptica* and *E.*
482 *miricola* species, but is yet to correctly identify *E. bruuniana*. Furthermore, genomic
483 exploration has provided insight into the breadth of the intrinsic MDR nature of
484 *Elizabethkingia* spp. and revealed a potential reservoir for infection within a hospital setting
485 where two patients were infected with near identical strains. Antimicrobial resistance data
486 suggests that clinical isolates are susceptible to fluoroquinolones, tetracyclines and
487 trimethoprim-sulfamethoxazole. In particular, minocycline and levofloxacin showed suitable
488 efficacy against *Elizabethkingia* isolates *in vitro*, although further clinical studies are required
489 to define optimal therapy.

490

491

492

493

494

495

496

497

498

499

500 **Acknowledgements**

501 <https://www.ncbi.nlm.nih.gov/bioproject/PRJNA576977>The authors wish to acknowledge the
502 Study Education and Research Committee of Pathology Queensland (LG), University of the
503 Sunshine Coast (DB), Advance Queensland (AQRF13016-17RD2 for DSS; AQIRF0362018
504 for EPP), and the National Health and Medical Research Council (GNT1157530 for PNAH)
505 for funding this study. We would like to express our gratitude to Mater Pathology, Sullivan
506 and Nicolaides Pathology, and Pathology Queensland for their involvement and support in
507 this project. Finally, we would like to thank the infection control nurses at participating
508 hospitals for environmental sampling.

509

510 **Conflicts of interest**

511 Dr. Paterson reports non-financial support from Ecolab Pty Ltd, Whiteley Corporation, and
512 Kimberly-Clark Professional, during the conduct of the study; personal fees from Merck,
513 Shionogi, Achaogen, AstraZeneca, Leo Pharmaceuticals, Bayer, GlaxoSmithKline, Cubist,
514 Venatorx, Accelerate and Pfizer; grants from Shionogi and Merck (MSD), outside the
515 submitted work. Dr. Harris reports grants from Merck (MSD) and Shionogi, personal fees
516 from Pfizer, outside the submitted work. All other authors declare no conflicts of interest.

517

518 **Tables and Figures**

519 Table 1. *Elizabethkingia* spp. isolates and associated speciation information included in the
 520 current study. Strain EkQ11, highlighted in purple represents a species identification error
 521 according to the VITEK[®] MS Knowledge Base v3.2.

Isolate ID	Age (y)	Date collected	Collection site	VITEK MS v3.2 ID	Whole Genome ID
EkQ1	1	2017	Sputum	<i>E. miricola</i>	<i>E. miricola</i>
EkQ3	43	2017	Sputum	<i>E. anophelis</i>	<i>E. anophelis</i>
EkQ4	78	2017	Blood	<i>E. meningoseptica</i>	<i>E. meningoseptica</i>
EkQ5	59	2017	Blood	<i>E. anophelis</i>	<i>E. anophelis</i>
EkQ6	17	2018	Bronchoalveolar lavage	<i>E. anophelis</i>	<i>E. anophelis</i>
EkQ7	69	2018	Blood	<i>E. anophelis</i>	<i>E. anophelis</i>
EkQ8	0	2018	Urine	<i>E. anophelis</i>	<i>E. anophelis</i>
EkQ10	34	2018	Sputum	<i>E. miricola</i>	<i>E. miricola</i>
EkQ11	85	2018	Blood	<i>E. miricola</i>	<i>E. bruuniana</i>
EkQ12	53	2018	Blood	<i>E. meningoseptica</i>	<i>E. meningoseptica</i>
EkQ13	1	2011	Sputum	<i>E. miricola</i>	<i>E. miricola</i>
EkQ15	16	2002	Bronchoalveolar lavage	<i>E. anophelis</i>	<i>E. anophelis</i>
EkQ16	82	2017	Blood	<i>E. anophelis</i>	<i>E. anophelis</i>
EkQ17	66	2018	Blood	<i>E. anophelis</i>	<i>E. anophelis</i>
EkM1	Unknown	2018	Unknown	<i>E. anophelis</i>	<i>E. anophelis</i>
EkM2	Unknown	2018	Unknown	<i>E. anophelis</i>	<i>E. anophelis</i>
EkM3	Unknown	2014	Unknown	<i>E. anophelis</i>	<i>E. anophelis</i>
EkS1	80	2013	Blood	<i>E. anophelis</i>	<i>E. anophelis</i>
EkS2	82	2015	Blood	<i>E. anophelis</i>	<i>E. anophelis</i>
EkS3	74	2016	Blood	<i>E. anophelis</i>	<i>E. anophelis</i>
EkS4	73	2012	Blood	<i>E. anophelis</i>	<i>E. anophelis</i>
EkS5	66	2018	Dialysis fluid	<i>E. anophelis</i>	<i>E. anophelis</i>
EK1	N/A	2019	Toilet sink drain, Oncology Ward	<i>E. anophelis</i>	<i>E. anophelis</i>
EK2	N/A	2019	Corridor sink drain, Infectious Disease Ward	<i>E. anophelis</i>	<i>E. anophelis</i>
EK3	N/A	2019	Hand washing drain, Oncology Ward	<i>E. anophelis</i>	<i>E. anophelis</i>
EK4	N/A	2019	Hand wash dink, Transplant Ward	<i>E. anophelis</i>	<i>E. anophelis</i>
EK5	N/A	2019	Toilet handrail, Transplant Ward	<i>E. anophelis</i>	<i>E. anophelis</i>
EK6	N/A	2019	Toilet sink, Transplant Ward	<i>E. anophelis</i>	<i>E. anophelis</i>

522

523

524

525

526 Table 2. Single nucleotide polymorphism and deletion differences between strains of the
 527 clonal cluster of clinical and environmental *Elizabethkingia anophelis* isolates. Clinical
 528 isolates EkQ5 (earliest collected and reference strain) and EkQ17 were collected from two
 529 different transplant patients, while Ek6 was collected from a shared handwashing sink on the
 530 transplant ward. Grey shading shows no differences, green shows similarities between EkQ17
 531 and EK6, while blue shading highlights unique changes. The proteins affected by each
 532 mutation and the resulting amino acid changes are also shown.

533


Mutation	EkQ5 2018	EkQ17 2018	EK6 2019	Protein affected	Effect
SNP	G	A	A	Hypothetical Protein	A10T
SNP	G	A	A	Efflux pump membrane transporter (bepE)	S416R
SNP	C	T	T	3-oxoacyl-[acyl-carrier-protein] synthase 2 (fabF)	R303H
SNP	T	C	C	Penicillin binding protein E (pbpE_7)	*762W (+ 279aa)
SNP	A	T	T	Sugar transporter	*133R (+ 133aa)
SNP	C	T	C	Hypothetical Protein	E168K
SNP	C	T	T	Protease (S41 family)	T161I
SNP	G	A	G	B-galactosidase (lacZ_2)	no change
DEL	CT	C	C	Hypothetical Protein	R65E (+ 9aa)

534


35 Table 3. Minimum inhibitory concentration data derived from broth microdilution testing of the 16 Australian *Elizabethkingia anophelis* clinical isolates
36 against 39 clinically relevant antimicrobials. White cells represent the range of concentration tested for each antimicrobial. EUCAST and CLSI breakpoints are
37 shown on the right where available. Blue and yellow cells indicate no breakpoint is currently available for this antimicrobial.

15 Table 4. Minimum inhibitory concentration data derived from broth microdilution testing of the 2 *Elizabethkingia meningoseptica* (blue) and 3 *Elizabethkingia*
16 *miricola* (orange) Australian clinical isolates against 39 clinically relevant antimicrobials. White cells represent the range of concentration tested for each
17 antimicrobial. EUCAST and CLSI breakpoints are shown on the right where available. Blue and yellow cells indicate no breakpoint is currently available for
18 this antimicrobial.

19



557 Figure 1. Global phylogenomic analysis of *Elizabethkingia* spp. genomes. Maximum
 558 parsimony midpoint-rooted phylogeny. Branches returning bootstrap support <0.8 are
 559 labelled. This phylogeny was reconstructed using 127,236 biallelic, orthologous single-
 560 nucleotide polymorphisms identified among the 128 *Elizabethkingia* genomes. Consistency
 561 index = 0.4066.



562 Figure 2. *Elizabethkingia anophelis* species specific phylogenomic analysis. Maximum
 563 parsimony midpoint-rooted phylogeny was reconstructed using 121,827 biallelic,
 564 orthologous single-nucleotide polymorphisms identified among the 71 *Elizabethkingia*
 565 *anophelis* genomes. Correctly speciated *Elizabethkingia anophelis* genomes are coloured
 566 green, incorrectly speciated *Elizabethkingia meningoseptica* genomes are coloured blue and

567 new *Elizabethkingia anophelis* genomes generated in this study are coloured black. Bootstrap
568 support <0.8 are labelled. Consistency index = 0.3110.

569

570

571

572


573

574

575

576

577



578

579

580 Figure 3. *Elizabethkingia miricola* species specific phylogenomic analysis. Maximum
581 parsimony midpoint-rooted phylogeny was reconstructed using 135,087 biallelic,
582 orthologous single-nucleotide polymorphisms identified among the 18 genomes. Correctly
583 speciated *E. miricola* strains are coloured orange, incorrectly speciated *Elizabethkingia*
584 *meningoseptica* coloured blue and *Elizabethkingia anophelis* genomes generated in this study
585 coloured black. Bootstrap support <0.80 is shown. Consistency index = 0.7404.


586

587

588

589

590



591

592

593 Figure 4. *Elizabethkingia meningoseptica* species specific phylogenomic analysis. Maximum
594 parsimony midpoint-rooted phylogeny was reconstructed using 61,500 biallelic, orthologous
595 single-nucleotide polymorphisms identified among the 22 genomes. Reference
596 *Elizabethkingia meningoseptica* strains are coloured blue with strains generated in this study
597 coloured black. Bootstrap support is 100 for all branches. Consistency index = 0.6895.

598

599


600

601

602

603

604



605

606 Figure 5. *Elizabethkingia bruuniana* species specific phylogenomic analysis. Maximum
607 parsimony midpoint-rooted phylogeny was reconstructed using 82,680 biallelic, orthologous
608 single-nucleotide polymorphisms identified among the 10 genomes. Correctly speciated
609 *Elizabethkingia bruuniana* strains are coloured red, incorrectly speciated *Elizabethkingia*
610 *miricola* strains are coloured orange and genomes generated in this study are coloured black.
611 Bootstrap support <0.8 is shown. Consistency index = 0.8729.

612

613

614

615

616

617 **Supplementary Material**

618 Table S1. Metadata and ID of the 100 *Elizabethkingia* NCBI and SRA reference genomes

619 used in this study.

620 Table S2: SPAdes and prokka genome assembly and annotation statistics of Australian

621 *Elizabethkingia* clinical isolates analysed in this study.

622

623 **References**

- 624 1. Moore, L. S. P. *et al.* Waterborne *Elizabethkingia meningoseptica* in Adult Critical
625 Care1. *Emerg. Infect. Dis.* **22**, 9–17 (2016).
- 626 2. Yung, C.-F. *et al.* *Elizabethkingia anophelis* and Association with Tap Water and
627 Handwashing, Singapore. *Emerg. Infect. Dis.* **24**, 1730–1733 (2018).
- 628 3. Nicholson, A. C. *et al.* Revisiting the taxonomy of the genus *Elizabethkingia* using
629 whole-genome sequencing, optical mapping, and MALDI-TOF, along with proposal of
630 three novel *Elizabethkingia* species: *Elizabethkingia bruuniana* sp. nov., *Elizabethkingia*
631 *ursingii* sp. nov., and *Elizabethkingia occulta* sp. nov. *Antonie Van Leeuwenhoek* **111**,
632 55–72 (2018).
- 633 4. Lin, J.-N., Lai, C.-H., Yang, C.-H. & Huang, Y.-H. *Elizabethkingia* Infections in
634 Humans: From Genomics to Clinics. *Microorganisms* **7**, 295 (2019).
- 635 5. Nicholson, A. C., Humrighouse, B. W., Graziano, J. C., Emery, B. & McQuiston, J. R.
636 Draft Genome Sequences of Strains Representing Each of the *Elizabethkingia*
637 Genomespecies Previously Determined by DNA-DNA Hybridization. *Genome Announc.*
638 **2**.
- 639 6. Perrin, A. *et al.* Evolutionary dynamics and genomic features of the *Elizabethkingia*
640 *anophelis* 2015 to 2016 Wisconsin outbreak strain. *Nat. Commun.* **8**, 15483 (2017).
- 641 7. Chew, K. L., Cheng, B., Lin, R. T. P. & Teo, J. W. P. *Elizabethkingia anophelis* Is the
642 Dominant *Elizabethkingia* Species Found in Blood Cultures in Singapore. *J. Clin.*
643 *Microbiol.* **56**, (2018).
- 644 8. Jean, S. S., Lee, W. S., Chen, F. L., Ou, T. Y. & Hsueh, P. R. *Elizabethkingia*
645 *meningoseptica*: an important emerging pathogen causing healthcare-associated
646 infections. *J. Hosp. Infect.* **86**, 244–249 (2014).

- 647 9. Frank, T. *et al.* First case of *Elizabethkingia anophelis* meningitis in the Central African
648 Republic. *Lancet Lond. Engl.* **381**, 1876 (2013).
- 649 10. Issack, M. I. & Neetoo, Y. An outbreak of *Elizabethkingia meningoseptica* neonatal
650 meningitis in Mauritius. *J. Infect. Dev. Ctries.* **5**, 834–839 (2011).
- 651 11. Teo, J. *et al.* First case of *E. anophelis* outbreak in an intensive-care unit. *The Lancet* **382**,
652 855–856 (2013).
- 653 12. Hsu, M.-S. *et al.* Clinical features, antimicrobial susceptibilities, and outcomes of
654 *Elizabethkingia meningoseptica* (*Chryseobacterium meningosepticum*) bacteremia at a
655 medical center in Taiwan, 1999–2006. *Eur. J. Clin. Microbiol. Infect. Dis.* **30**, 1271–1278
656 (2011).
- 657 13. Choi, M. H. *et al.* Risk Factors for *Elizabethkingia* Acquisition and Clinical
658 Characteristics of Patients, South Korea. *Emerg. Infect. Dis.* **25**, 42–51 (2019).
- 659 14. Janda, J. M. & Lopez, D. L. Mini review: New pathogen profiles: *Elizabethkingia*
660 *anophelis*. *Diagn. Microbiol. Infect. Dis.* **88**, 201–205 (2017).
- 661 15. Weaver, K. N. *et al.* Acute emergence of *Elizabethkingia meningoseptica* infection
662 among mechanically ventilated patients in a long-term acute care facility. *Infect. Control*
663 *Hosp. Epidemiol.* **31**, 54–58 (2010).
- 664 16. Chawla, K., Gopinathan, A., Varma, M. & Mukhopadhyay, C. *Elizabethkingia*
665 *Meningoseptica* Outbreak in Intensive Care Unit. *J. Glob. Infect. Dis.* **7**, 43–44 (2015).
- 666 17. Kyritsi, M. A., Mouchtouri, V. A., Pournaras, S. & Hadjichristodoulou, C. First reported
667 isolation of an emerging opportunistic pathogen (*Elizabethkingia anophelis*) from
668 hospital water systems in Greece. *J. Water Health* **16**, 164–170 (2018).
- 669 18. Doijad, S., Ghosh, H., Glaeser, S., Kämpfer, P. & Chakraborty, T. Taxonomic
670 reassessment of the genus *Elizabethkingia* using whole-genome sequencing:
671 *Elizabethkingia endophytica* Kämpfer et al. 2015 is a later subjective synonym of

- 672 *Elizabethkingia anophelis* Kämpfer et al. 2011. *Int. J. Syst. Evol. Microbiol.* **66**, 4555–
673 4559 (2016).
- 674 19. Li, Y. et al. *Chryseobacterium miricola* sp. nov., A Novel Species Isolated from
675 Condensation Water of Space Station Mir. *Syst. Appl. Microbiol.* **26**, 523–528 (2003).
- 676 20. Kämpfer, P. et al. *Elizabethkingia anophelis* sp. nov., isolated from the midgut of the
677 mosquito *Anopheles gambiae*. *Int. J. Syst. Evol. Microbiol.* **61**, 2670–2675 (2011).
- 678 21. Jorgensen, J. H. & P. Faller, M. A. Introduction to the 11th Edition of the Manual of
679 Clinical Microbiology. *Man. Clin. Microbiol. Elev. Ed.* 3–4 (2015)
680 doi:10.1128/9781555817381.ch1.
- 681 22. Lau, S. K. P. et al. *Elizabethkingia anophelis* bacteremia is associated with clinically
682 significant infections and high mortality. *Sci. Rep.* **6**, (2016).
- 683 23. Lin, J.-N., Lai, C.-H., Yang, C.-H., Huang, Y.-H. & Lin, H.-H. Clinical manifestations,
684 molecular characteristics, antimicrobial susceptibility patterns and contributions of target
685 gene mutation to fluoroquinolone resistance in *Elizabethkingia anophelis*. *J. Antimicrob.*
686 *Chemother.* **73**, 2497–2502 (2018).
- 687 24. Han, M.-S. et al. Relative Prevalence and Antimicrobial Susceptibility of Clinical
688 Isolates of *Elizabethkingia* Species Based on 16S rRNA Gene Sequencing. *J. Clin.*
689 *Microbiol.* **55**, 274–280 (2017).
- 690 25. Lin, J.-N., Lai, C.-H., Yang, C.-H. & Huang, Y.-H. Comparison of Clinical
691 Manifestations, Antimicrobial Susceptibility Patterns, and Mutations of Fluoroquinolone
692 Target Genes between *Elizabethkingia meningoseptica* and *Elizabethkingia anophelis*
693 Isolated in Taiwan. *J. Clin. Med.* **7**, (2018).
- 694 26. Lin, Y.-T. et al. Clinical and microbiological analysis of *Elizabethkingia meningoseptica*
695 bacteremia in adult patients in Taiwan. *Scand. J. Infect. Dis.* **41**, 628–634 (2009).

- 696 27. Tai, I.-C. *et al.* Outbreak of *Elizabethkingia meningoseptica* sepsis with meningitis in a
697 well-baby nursery. *J. Hosp. Infect.* **96**, 168–171 (2017).
- 698 28. Jian, M.-J. *et al.* Fluoroquinolone resistance in carbapenem-resistant *Elizabethkingia*
699 *anophelis*: phenotypic and genotypic characteristics of clinical isolates with
700 topoisomerase mutations and comparative genomic analysis. *8* (2019).
- 701 29. Jean, S.-S., Hsieh, T.-C., Ning, Y.-Z. & Hsueh, P.-R. Role of vancomycin in the
702 treatment of bacteraemia and meningitis caused by *Elizabethkingia meningoseptica*. *Int.*
703 *J. Antimicrob. Agents* **50**, 507–511 (2017).
- 704 30. Chang, T.-Y., Chen, H.-Y., Chou, Y.-C., Cheng, Y.-H. & Sun, J.-R. In vitro activities of
705 imipenem, vancomycin, and rifampicin against clinical *Elizabethkingia* species producing
706 BlaB and GOB metallo-beta-lactamases. *Eur. J. Clin. Microbiol. Infect. Dis.* (2019)
707 doi:10.1007/s10096-019-03639-3.
- 708 31. Han, M.-S. *et al.* Relative Prevalence and Antimicrobial Susceptibility of Clinical
709 Isolates of *Elizabethkingia* Species Based on 16S rRNA Gene Sequencing. *J. Clin.*
710 *Microbiol.* **55**, 274–280 (2017).
- 711 32. Bolger, A. M., Lohse, M., & Usadel, B. Trimmomatic: A flexible trimmer for Illumina
712 Sequence Data. *Bioinforma. Btu170* (2014).
- 713 33. Ewels, P., Magnusson, M., Lundin, S. & Källér, M. MultiQC: summarize analysis results
714 for multiple tools and samples in a single report. *Bioinformatics* **32**, 3047–3048 (2016).
- 715 34. H. Li. Seqtk: a fast and lightweight tool for processing FASTA or FASTQ sequences.
716 (2013).
- 717 35. Huang, W., Li, L., Myers, J. R. & Marth, G. T. ART: a next-generation sequencing read
718 simulator. *Bioinformatics* **28**, 593–594 (2012).

- 719 36. Nurk, S. *et al.* Assembling Genomes and Mini-metagenomes from Highly Chimeric
720 Reads. in *Research in Computational Molecular Biology* (eds. Deng, M., Jiang, R., Sun,
721 F. & Zhang, X.) 158–170 (Springer Berlin Heidelberg, 2013).
- 722 37. Seemann, T. Prokka: rapid prokaryotic genome annotation. *Bioinforma. Oxf. Engl.* **30**,
723 2068–2069 (2014).
- 724 38. Sarovich, D. S. & Price, E. P. SPANDx: a genomics pipeline for comparative analysis of
725 large haploid whole genome re-sequencing datasets. *BMC Res. Notes* **7**, 618 (2014).
- 726 39. Swofford, D. L. PAUP* ver 4.0. b10. *Phylogenetic Anal. Using Parsimony Methods*
727 *Sunderland MA Sinauer Assoc. Sunderland* (2003).
- 728 40. Using Tablet for visual exploration of second-generation sequencing data | Briefings in
729 Bioinformatics | Oxford Academic.
730 <https://academic.oup.com/bib/article/14/2/193/208254>.
- 731 41. Kearse, M. *et al.* Geneious Basic: an integrated and extendable desktop software platform
732 for the organization and analysis of sequence data. *Bioinforma. Oxf. Engl.* **28**, 1647–1649
733 (2012).
- 734 42. Aziz, R. K. *et al.* The RAST Server: rapid annotations using subsystems technology.
735 *BMC Genomics* **9**, 75 (2008).
- 736 43. Kahlmeter, G. *et al.* European Committee on Antimicrobial Susceptibility Testing
737 (EUCAST) Technical Notes on antimicrobial susceptibility testing. *Clin. Microbiol.*
738 *Infect.* **12**, 501–503 (2006).
- 739 44. Clinical and Laboratory Standards Institute. CLSI guideline M45. Methods for
740 Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or
741 Fastidious Bacteria. 3rd ed, Wayne, PA: Clinical and Laboratory Standards Institute;
742 2016.

- 743 45. Jorgensen, J. H., Hindler, J. F., Reller, L. B. & Weinstein, M. P. New Consensus
744 Guidelines from the Clinical and Laboratory Standards Institute for Antimicrobial
745 Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria. *Clin. Infect. Dis.*
746 **44**, 280–286 (2007).
- 747 46. Clinical and Laboratory Standards Institute. 2015. M7-A10: methods for dilution
748 antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard,
749 10th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
- 750 47. Brettin, T. *et al.* RASTtk: a modular and extensible implementation of the RAST
751 algorithm for building custom annotation pipelines and annotating batches of genomes.
752 *Sci. Rep.* **5**, 8365 (2015).
- 753 48. Overbeek, R. *et al.* The SEED and the Rapid Annotation of microbial genomes using
754 Subsystems Technology (RAST). *Nucleic Acids Res.* **42**, D206-214 (2014).
- 755 49. Lin, J.-N., Lai, C.-H., Yang, C.-H., Huang, Y.-H. & Lin, H.-H. Genomic features,
756 phylogenetic relationships, and comparative genomics of *Elizabethkingia anophelis* strain
757 EM361-97 isolated in Taiwan. *Sci. Rep.* **7**, (2017).
- 758 50. Breurec, S. *et al.* Genomic epidemiology and global diversity of the emerging bacterial
759 pathogen *Elizabethkingia anophelis*. *Sci. Rep.* **6**, (2016).
- 760 51. Johnson, W. L. *et al.* The draft genomes of *Elizabethkingia anophelis* of equine origin are
761 genetically similar to three isolates from human clinical specimens. *PLOS ONE* **13**,
762 e0200731 (2018).
- 763 52. Teo, J. *et al.* Comparative Genomic Analysis of Malaria Mosquito Vector-Associated
764 Novel Pathogen *Elizabethkingia anophelis*. *Genome Biol. Evol.* **6**, 1158–1165 (2014).
- 765 53. Tagoe, D. N. A., Baidoo, S., Dadzie, I., Tengey, D. & Agedo, C. Potential Sources of
766 Transmission of Hospital Acquired Infections in the Volta Regional Hospital in Ghana.
767 *Ghana Med. J.* **45**, 22–26 (2011).

- 768 54. Khan, H. A., Baig, F. K. & Mehboob, R. Nosocomial infections: Epidemiology,
769 prevention, control and surveillance. *Asian Pac. J. Trop. Biomed.* **7**, 478–482 (2017).
- 770 55. Lau, S. K. P. *et al.* Evidence for *Elizabethkingia anophelis* transmission from mother to
771 infant, Hong Kong. *Emerg. Infect. Dis.* **21**, 232–241 (2015).
- 772 56. Lin, J.-N., Lai, C.-H., Yang, C.-H., Huang, Y.-H. & Lin, H.-H. Genomic Features,
773 Comparative Genomics, and Antimicrobial Susceptibility Patterns of *Elizabethkingia*
774 *bruuniana*. *Sci. Rep.* **9**, 2267 (2019).
- 775 57. Bellais, S., Poirel, L., Naas, T., Girlich, D. & Nordmann, P. Genetic-biochemical analysis
776 and distribution of the Ambler class A beta-lactamase CME-2, responsible for extended-
777 spectrum cephalosporin resistance in *Chryseobacterium* (Flavobacterium)
778 *meningosepticum*. *Antimicrob. Agents Chemother.* **44**, 1–9 (2000).
- 779 58. Rossolini, G. M. *et al.* Cloning of a *Chryseobacterium* (Flavobacterium)
780 *meningosepticum* chromosomal gene (blaA(CME)) encoding an extended-spectrum class
781 A beta-lactamase related to the Bacteroides cephalosporinases and the VEB-1 and PER
782 beta-lactamases. *Antimicrob. Agents Chemother.* **43**, 2193–2199 (1999).
- 783 59. Colapietro, M. *et al.* BlaB-15, a new BlaB metallo-beta-lactamase variant found in an
784 *Elizabethkingia miricola* clinical isolate. *Diagn. Microbiol. Infect. Dis.* **85**, 195–197
785 (2016).
- 786 60. Jian, M.-J., Cheng, Y.-H., Perng, C.-L. & Shang, H.-S. Molecular typing and profiling of
787 topoisomerase mutations causing resistance to ciprofloxacin and levofloxacin in
788 *Elizabethkingia* species. *PeerJ* **6**, (2018).
- 789 61. Wang, M. *et al.* The antibiotic resistance and pathogenicity of a multidrug-resistant
790 *Elizabethkingia anophelis* isolate. *MicrobiologyOpen* **0**, e804.
- 791 62. Opota, O. *et al.* Genome of the carbapenemase-producing clinical isolate *Elizabethkingia*
792 *miricola* EM_CHUV and comparative genomics with *Elizabethkingia meningoseptica*

- 793 and *Elizabethkingia anophelis*: evidence for intrinsic multidrug resistance trait of
794 emerging pathogens. *Int. J. Antimicrob. Agents* **49**, 93–97 (2017).
- 795 63. Balm, M. N. *et al.* Bad design, bad practices, bad bugs: frustrations in controlling an
796 outbreak of *Elizabethkingia meningoseptica* in intensive care units. *J Hosp Infect* **85**,
797 134–40 (2013).
- 798 64. Huang, Y.-C., Lin, Y.-T. & Wang, F.-D. Comparison of the therapeutic efficacy of
799 fluoroquinolone and non-fluoroquinolone treatment in patients with *Elizabethkingia*
800 *meningoseptica* bacteraemia. *Int. J. Antimicrob. Agents* **51**, 47–51 (2018).
- 801 65. Chan, J. C. *et al.* Invasive paediatric *Elizabethkingia meningoseptica* infections are best
802 treated with a combination of piperacillin/tazobactam and trimethoprim/sulfamethoxazole
803 or fluoroquinolone. *J. Med. Microbiol.* **68**, 1167–1172 (2019).
- 804 66. Bassetti, M., Peghin, M., Vena, A. & Giacobbe, D. R. Treatment of Infections Due to
805 MDR Gram-Negative Bacteria. *Front. Med.* **6**, (2019).
- 806 67. Hackel, M. A. *et al.* In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol,
807 against Carbapenem-Nonsusceptible and Multidrug-Resistant Isolates of Gram-Negative
808 Bacilli Collected Worldwide in 2014 to 2016. *Antimicrob. Agents Chemother.* **62**, (2018).
- 809 68. Haidar, G. *et al.* Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant
810 *Pseudomonas aeruginosa* Infections: Clinical Effectiveness and Evolution of Resistance.
811 *Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am.* **65**, 110–120 (2017).
- 812 69. Shields, R. K. *et al.* Verification of Ceftazidime-Avibactam and Ceftolozane-Tazobactam
813 Susceptibility Testing Methods against Carbapenem-Resistant Enterobacteriaceae and
814 *Pseudomonas aeruginosa*. *J. Clin. Microbiol.* **56**, (2018).
- 815 70. Zhanel, G. G. *et al.* Cefiderocol: A Siderophore Cephalosporin with Activity Against
816 Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli. *Drugs* **79**, 271–
817 289 (2019).

